Stocktoria
MYRIAD GENETICS INC MYGN
Nasdaq · XNAS · stock · In Vitro & In Vivo Diagnostic Substances · website · IPO 1995-10-06
MYRIAD GENETICS INC financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $824.5M | $837.6M | $753.2M | $678.4M | $690.6M |
| Gross profit | $576.6M | $585.4M | $517.0M | $476.4M | — |
| R&D expense | $106.8M | $113.4M | $88.7M | $85.4M | $81.9M |
| SG&A expense | — | — | $572.9M | $514.7M | $537.8M |
| Operating income | -$387.2M | -$123.5M | -$257.4M | -$140.6M | -$190.5M |
| Interest expense | — | — | $2.9M | $3.2M | $6.6M |
| Income tax | -$29.2M | $3.8M | $1.1M | -$28.6M | -$29.9M |
| Net income | -$365.9M | -$127.3M | -$263.3M | -$112.0M | -$27.2M |
| EPS (diluted) | $-3.95 | $-1.41 | $-3.18 | $-1.39 | $-0.35 |
| Operating cash flow | $1.8M | -$8.7M | -$110.9M | -$106.3M | $18.6M |
| Cash & equivalents | $149.6M | $102.4M | $132.1M | $56.9M | $257.4M |
| Inventory | $30.6M | $27.5M | $22.0M | $20.1M | $15.3M |
| Total assets | $706.6M | $1.0B | $1.1B | $1.2B | $1.3B |
| Total liabilities | $338.6M | $326.5M | $363.3M | $312.9M | $352.9M |
| Shareholders' equity | $368.0M | $701.1M | $783.2M | $885.8M | $967.8M |
Source: SEC EDGAR filings · CIK 0000899923 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.